DurAVR™

THE FIRST-IN-CLASS BIOMIMETIC TAVR VALVE SHAPED FOR NATIVE PERFORMANCE
The first-in-class Biomimetic TAVR valve shaped for native performance

LIVE IN THE CATH LAB

Watch Anteris Technologies CEO, Wayne Paterson, connect live to the Cath Lab in Tbilisi, Georgia for an update on the DurAVR™ THV First In Human study with implanting physicians.

PCR LONDON VALVES 2023 PHYSICIAN PANEL INTERVIEW

Watch this physician panel and hear Drs Michael Reardon, Christopher Meduri, and Azeem Latib discuss the design of the DurAVR™ THV and the paradigm-shifting haemodynamic results from the Early Feasibility Study (EFS).

PCR-LV 2023 DURAVR™ THV EFS & FIH DATA PRESENTATION

See the Early Feasibility Study (EFS) data presented at PCR London Valves 2023, showing excellent sustained haemodynamic performance at 30 days post-implantation.

View Presentation
See the Early Feasibility Study (EFS) data presented at PCR London Valves 2023, showing excellent sustained haemodynamic performance at 30 days post-implantation.

TVT 2023 DURAVR™ THV DATA PRESENTATION

See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.

View Data
Anteris Technologies Heart Valve DurAVR

TCT 2023 PHYSICIAN PANEL INTERVIEW

Watch this physician panel and hear Drs Michael Reardon, Rebecca Hahn, Christopher Meduri, and Azeem Latib discuss the design of the DurAVR™ THV and its impact on haemodynamics.

TCT 2023 DURAVR™ THV EFS DATA PRESENTATION

See the Early Feasibility Study (EFS) discharge data presented at TCT 2023, showing remarkable haemodynamic performance.

View Presentation
See the Early Feasibility Study (EFS) discharge data presented at TCT 2023, showing remarkable haemodynamic performance.

TVT 2023 DURAVR™ THV DATA PRESENTATION

See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.

View Data
Anteris Technologies Heart Valve DurAVR

TCT 2023 DURAVR™ THV FIH DATA PRESENTATION

See the latest First-in-Human (FIH) Study data presented at TCT 2023, showing sustained mean haemodynamic performance from all 20 patients at 6 months post-procedure.

View Presentation
See the latest First-in-Human (FIH) Study data presented at TCT 2023, showing sustained mean haemodynamic performance from all 20 patients at 6 months post-procedure.

TVT 2023 DURAVR™ THV DATA PRESENTATION

See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.

View Data
Anteris Technologies Heart Valve DurAVR

TVT 2023 DURAVR™ THV DATA PRESENTATION

See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.

View Data
TVT 2023 DURAVR™ THV DATA PRESENTATION

TVT 2023 DURAVR™ THV DATA PRESENTATION

See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.

View Data
Anteris Technologies Heart Valve DurAVR

ANNUAL GENERAL MEETING, 29 MAY 2023

Watch the live presentation given by CEO Wayne Paterson, at this year's Annual General Meeting hosted by Anteris on the 29 May 2023. 

LEARN MORE

EUROPCR 2023 PHYSICIAN PANEL

Watch this physician panel and hear Drs Christopher Meduri, Susheel Kodali, and João Cavalcante discuss early safety and feasibility of the first-in-class biomimetic transcatheter aortic valve – DurAVR™ THV.

LIVE PHYSICIAN INTERVIEW AT AGM

CEO Wayne Paterson and Dr. Karl Poon discuss his experience with DurAVR™ at Anteris Technologies’ Annual General Meeting.

POWERED BY SCIENCE. DEVELOPED BY EXPERTS.

Shaped for native haemodynamic performance for patients with severe aortic stenosis, DurAVR™ Transcatheter Heart Valve elevates science.

LEARN MORE
Anteris Technologies Heart Valve DurAVR

POWERED BY SCIENCE. DEVELOPED BY EXPERTS.

Shaped for native haemodynamic performance for patients with severe aortic stenosis, DurAVR™ Transcatheter Heart Valve elevates science.

LEARN MORE
Anteris Technologies Heart Valve DurAVR

INSPIRED BY PATIENTS. EMPOWERED BY PURPOSE.

Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.

INVEST IN ANTERIS (ASX: AVR)

We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Investors
Anteris Technologies Invest AVR ASX

INVEST IN ANTERIS (ASX: AVR)

We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.

Investors
Anteris Technologies Invest AVR ASX

LATEST ANTERIS NEWS

LATEST ANTERIS NEWS

US EFS DATA LANDING PAGE

Explore the highlights from DurAVR™ data presented at TCT & PCR LV 2023

View Here
DurAVR™: A New Class of TAVR data release at TCT 2023

TVT 2023 DATA PRESENTATION

DurAVR™ THV First-In-Human Presentation with Updated Results

View Data
DurAVR™ THV First-In-Human Presentation with Updated Results

ANNUAL GENERAL MEETING

 

 

 

VIEW PRESENTATION
FDA Grants Anteris Expanded Approval for Anteris